Free tool
FAERS Monitor: Caplyta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209500 or its brand name (Caplyta, Lumateperone Tosylate). Reports on generic versions are filed under their own applications.
Reports
7,706
Serious
2,180
28% of reports
Hospitalization
616
Death reported
65
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness754
- nausea581
- headache523
- somnolence448
- off label use407
- drug ineffective357
- mania315
- anxiety308
- sedation292
- feeling abnormal291
- insomnia279
- fatigue275
- vomiting257
- suicidal ideation244
- burning sensation225
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 170 |
| 2021 | 363 |
| 2022 | 980 |
| 2023 | 622 |
| 2024 | 1,997 |
| 2025 | 1,611 |
| 2026 | 1,961 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,453 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| maniaSignal | 315 | 53.3 | 47.8 | 15,806 |
| sedationSignal | 292 | 30.8 | 27.5 | 8,296 |
| burning sensationSignal | 225 | 8.8 | 7.7 | 1,544 |
| suicidal ideationSignal | 244 | 7.3 | 6.4 | 1,321 |
| somnolenceSignal | 448 | 6.1 | 5.6 | 1,912 |
| dizzinessSignal | 754 | 4.1 | 3.9 | 1,827 |
| feeling abnormalSignal | 291 | 3.3 | 3.0 | 474 |
| anxietySignal | 308 | 3.0 | 2.6 | 402 |
| insomniaSignal | 279 | 2.9 | 2.5 | 340 |
| headacheSignal | 523 | 2.3 | 2.1 | 385 |
| nauseaSignal | 581 | 2.0 | 1.9 | 303 |
| vomiting | 257 | 1.5 | 1.3 | 42 |
| off label use | 407 | 1.3 | 1.2 | 24 |
| fatigue | 275 | 1.0 | 0.9 | 0 |
| drug ineffective | 357 | 0.7 | 0.7 | 35 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.